In our study, WKYMVm treatment led to decreased production of myofibroblasts positive for α-SMA, Vimentin, and phospho-SMAD3 through an Fpr2-dependent mechanism in the scleroderma model. The gene discussed is SMAD3; the disease is scleroderma.